Aardvark Therapeutics (AARD) Accounts Payables (2024 - 2026)
Aardvark Therapeutics (AARD) posted Accounts Payables of $4.5 million for Q1 2026, up 116.84% sequentially from $2.1 million in Q4 2025, and up 75.78% YoY from $2.6 million in Q1 2025.
Aardvark Therapeutics (AARD) Accounts Payables (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Accounts Payables for 3 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Accounts Payables rose 75.78% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 75.78% YoY) and the FY2025 annual result came in at $2.1 million, down 9.83% from the prior year.
- Accounts Payables improved to $4.5 million in Q1 2026 per AARD's latest filing, from $2.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $5.1 million in Q2 2025 and troughed at $2.1 million in Q4 2025.
- A 3-year average of $3.5 million and a median of $3.5 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2025 and 2026: Accounts Payables fell 9.83% in 2025, then jumped 75.78% in 2026.
- Over 3 years, Accounts Payables stood at $2.3 million in 2024, then retreated by 9.83% to $2.1 million in 2025, then surged by 116.84% to $4.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $4.5 million, $2.1 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 2.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.09 Mn |
| Mar 31, 2026 | 4.49 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 4.44 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | 2.30 Mn |